We are live on
!
Find out more
APM
Avidity Partners Management Portfolio holdings
AUM
$936M
1-Year Est. Return
195%
This Fund
S&P 500
This Quarter
Est. Return
+6.68%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$1.86B
AUM Growth
+$296M
(+19%)
Cap. Flow
+$355M
Cap. Flow
% of AUM
19.12%
Top 10 Holdings %
Top 10 Hldgs %
45.66%
Holding
101
New
43
Increased
15
Reduced
8
Closed
34
Top Buys
| 1 |
Merck
MRK
|
+$93.9M |
| 2 |
Biogen
BIIB
|
+$87.9M |
| 3 |
Akebia Therapeutics
AKBA
|
+$64.3M |
| 4 |
Avantor
AVTR
|
+$61.3M |
| 5 |
Thermo Fisher Scientific
TMO
|
+$48.9M |
Top Sells
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$82.4M |
| 2 |
IMMU
Immunomedics Inc
IMMU
|
+$67.7M |
| 3 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$57M |
| 4 |
HOLX
Hologic
HOLX
|
+$46.6M |
| 5 |
Exelixis
EXEL
|
+$44.9M |
Sector Composition
| 1 | Healthcare | 93.04% |
| 2 | Technology | 1.98% |
| 3 | Industrials | 0.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
CALL
Pfizer
PFE
$141B
| $239M | 12.85% |
+6,851,000
| New | +$240M |
|
2
AbbVie
ABBV
$431B
| $133M | 7.18% |
1,522,800
-22,600
| -1% | -$2.13M |
|
|
SGEN
3
DELISTED
Seagen Inc. Common Stock
SGEN
| $104M | 5.6% |
531,100
+280,200
| +112% | +$46.9M |
|
|
4
Avantor
AVTR
$7.65B
| $103M | 5.53% |
4,562,400
+2,950,400
| +183% | +$61.3M |
|
|
5
Merck
MRK
$305B
| $94.9M | 5.11% |
+1,199,226
| New | +$93.9M |
|
|
6
Biogen
BIIB
$29.1B
| $89.4M | 4.81% |
+315,100
| New | +$87.9M |
|
|
BHVN
7
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $83.5M | 4.5% |
1,284,200
+179,700
| +16% | +$11.8M |
|
|
HZNP
8
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $72.3M | 3.89% |
930,200
+394,000
| +73% | +$27.1M |
|
|
NBP
9
NovaBridge Biosciences American Depositary Shares
NBP
$214M
| $63M | 3.39% |
+1,340,000
| New | +$44.2M |
|
|
10
CALL
Biogen
BIIB
$29.1B
| $60.7M | 3.27% |
+214,100
| New | +$59.7M |
|
11
Aurinia Pharmaceuticals
AUPH
$2.07B
| $52.5M | 2.83% |
3,564,900
+1,090,301
| +44% | +$15.8M |
|
|
12
Thermo Fisher Scientific
TMO
$199B
| $52.2M | 2.81% |
+118,300
| New | +$48.9M |
|
|
BMY.RT
13
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
| $51M | 2.75% |
22,684,932
+16,897,991
| +292% | +$48.3M |
|
14
Baxter International
BAX
$11.4B
| $49.9M | 2.69% |
620,000
-180,900
| -23% | -$15.2M |
|
15
Elevance Health
ELV
$84.8B
| $47.4M | 2.55% |
+176,400
| New | +$47.5M |
|
16
Quest Diagnostics
DGX
$22.3B
| $46M | 2.48% |
+402,000
| New | +$47.5M |
|
|
MRTX
17
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $45.7M | 2.46% |
+275,000
| New | +$37.6M |
|
18
QuidelOrtho
QDEL
$1.24B
| $38.8M | 2.09% |
+176,879
| New | +$39.5M |
|
19
Boston Scientific
BSX
$64B
| $37M | 1.99% |
+967,100
| New | +$37.3M |
|
|
CHNG
20
DELISTED
Change Healthcare Inc. Common Stock
CHNG
| $36.7M | 1.98% |
+2,527,500
| New | +$32.1M |
|
21
Natera
NTRA
$39.7B
| $36.4M | 1.96% |
+503,400
| New | +$28.6M |
|
|
KDMN
22
DELISTED
Kadmon Holdings, Inc.
KDMN
| $35.4M | 1.91% |
9,030,000
+2,603,300
| +41% | +$10.9M |
|
23
Arvinas
ARVN
$534M
| $31.8M | 1.71% |
1,348,300
+271,400
| +25% | +$7.87M |
|
24
Zentalis Pharmaceuticals
ZNTL
$340M
| $29.6M | 1.59% |
904,119
+229,632
| +34% | +$8.04M |
|
25
Syndax Pharmaceuticals
SNDX
$2.08B
| $27.4M | 1.47% |
1,854,100
+326,700
| +21% | +$4.98M |
|
Similar funds
NM
LM
IF
PWAM
CM
LJAC
PO
SH